Australia Lab Automation Market Research Report: Trends, Forecast & Opportunities (2026-2032)

Australia Lab Automation Market Report Key Takeaways:

• The Australia Lab Automation Market size was valued at around USD 114 million in 2025 and is projected grow from USD 121 million in 2026 to USD 175 million by 2032, exhibiting a CAGR of 6.34% during the forecast period.
• By Product Type, the Equipment / Devices segment represented a significant share of about 55% in the Australia Lab Automation Market in 2026.
• By End User, the Pharmaceutical & Biotechnology Companies seized a significant share of about 42% in the Australia Lab Automation Market in 2026.
• Leading companies are Thermo Fisher Scientific, Siemens Healthineers, F. Hoffmann-La Roche Ltd, Danaher Corporation, Agilent Technologies, Tecan Group Ltd., Hamilton Company, Revvity, Inc., Abbott Laboratories, Becton, Dickinson and Company (BD), and Others.

Market Insights & Analysis: Australia Lab Automation Market (2026-32):

The Australia Lab Automation Market size was valued at around USD 114 million in 2025 and is projected grow from USD 121 million in 2026 to USD 175 million by 2032, exhibiting a CAGR of 6.34% during the forecast period, i.e., 2026-32.

Australia’s laboratory automation market has demonstrated steady historical expansion, supported by rising diagnostic demand and sustained healthcare investment. According to the Australian Institute of Health and Welfare, total health expenditure exceeded USD 178 billion in 2023–24, reflecting strong infrastructure funding. High volumes of pathology and diagnostic testing have encouraged laboratories to adopt automation technologies to improve throughput and accuracy. Over time, centralized laboratory networks and technology upgrades have strengthened automation penetration across clinical and research settings.

Current market conditions are driven by strong institutional demand, particularly from hospitals and diagnostic laboratories. Major providers such as Sonic Healthcare and Healius Limited continue expanding high-throughput laboratory infrastructure to manage increasing sample volumes. The Australian Bureau of Statistics reports that healthcare and social assistance account for over 15% of national employment, indicating sustained sector expansion . This institutional dominance reinforces demand for automation to ensure efficiency, scalability, and rapid turnaround times.

Regulatory and policy frameworks have played a critical role in supporting market growth through digital transformation initiatives. The Australian Digital Health Agency is advancing national programs focused on electronic health records and data interoperability, enabling integration with automated laboratory systems. In addition, government funding through Medicare continues to allocate billions of dollars annually toward pathology services, reinforcing testing demand. These policy measures support the adoption of automation technologies by improving data management, compliance, and operational efficiency in laboratories.

Looking ahead, the market outlook remains positive, supported by demographic shifts and ongoing technological innovation. According to the Australian Bureau of Statistics, the population aged 65 and above is projected to exceed 20% in the coming decades, increasing diagnostic demand . Companies such as Thermo Fisher Scientific are investing in AI-enabled automation and advanced workflows to enhance productivity. Combined with continued digital health initiatives and infrastructure investments, these factors are expected to sustain long-term growth in laboratory automation adoption.

Australia Lab Automation Market Recent Developments:

• 2025 : Roche Diagnostics reported increased adoption of automation in clinical laboratories, emphasizing pre-analytical and workflow automation to improve efficiency and reduce manual errors across global and Australia-linked lab networks.

Australia Lab Automation Market Scope:

Australia Lab Automation Market Driver:

Rising Diagnostic Testing Demand

Rising diagnostic testing demand has emerged as the most influential structural driver of Australia’s laboratory automation market, driven by the increasing burden of chronic diseases. According to the Australian Institute of Health and Welfare, around 6 in 10 Australians live with at least one long-term health condition, while chronic diseases account for nearly two-thirds of the total disease burden. Conditions such as cardiovascular disease, diabetes, and cancer require continuous monitoring and frequent testing. This sustained clinical demand directly increases laboratory workloads, necessitating scalable and automated diagnostic solutions.

The measurable impact of this driver is evident in the growing volume and frequency of diagnostic testing across institutional end users. Data from the Australian Bureau of Statistics indicates that cardiovascular disease alone affects approximately 1.3 million Australians, while diabetes contributes to over 21,000 deaths annually, reinforcing the need for ongoing diagnostic evaluation. Hospitals and diagnostic laboratories are experiencing higher sample volumes due to repeated testing requirements for chronic disease management. This sustained increase in testing frequency has intensified the need for automation to maintain efficiency, accuracy, and turnaround times.

Government funding has further strengthened this structural demand by expanding access to diagnostic services. The Australian government committed approximately USD 5.4 billion in 2025 to strengthen Medicare, increasing accessibility to primary care and pathology testing. This policy-driven expansion is directly contributing to higher testing volumes and sustained laboratory utilization. Combined with digital health initiatives led by the Australian Digital Health Agency, these factors establish a clear cause-and-effect relationship, where increased healthcare access drives diagnostic demand and accelerates laboratory automation adoption.

Australia Lab Automation Market Trend:

Integration of AI with Laboratory Automation

The integration of artificial intelligence (AI) with laboratory automation has emerged as a defining structural trend, driven by increasing data complexity and the need for high-throughput efficiency. Laboratories are generating large volumes of diagnostic and research data, requiring advanced analytics and automation for effective utilization. According to the Australian Digital Health Agency, national initiatives are accelerating digital health integration and interoperability. This has created a strong foundation for adopting AI-enabled laboratory systems across Australia .

This trend is reshaping laboratory operations by combining automation infrastructure with intelligent data-driven systems. In 2025, Abacus dx partnered with Inpeco to expand total laboratory automation solutions in Australia, enhancing workflow connectivity and data traceability. Building on this, in 2026, LabVantage introduced Cortex, an AI-enabled LIMS platform supporting autonomous workflows and predictive quality control . Together, these developments illustrate the convergence of automation hardware and AI-driven software, transforming laboratories into connected and intelligent ecosystems.

The persistence of this trend is supported by measurable adoption data and continued investment in digital infrastructure. A global survey by the Pistoia Alliance indicates that 68% of laboratories already use AI or machine learning, with many planning further adoption . Additionally, government funding exceeding USD 150 million for digital health upgrades in 2025–26 is strengthening system integration capabilities. As laboratories seek improved efficiency, accuracy, and scalability, AI-driven automation is expected to remain central to long-term market evolution.

Australia Lab Automation Market Opportunity:

Expanding Healthcare Infrastructure in Australia

The expansion of healthcare infrastructure in Australia represents a compelling market opportunity, driven by sustained government investment and large-scale hospital development projects. In 2025, the Australian government committed approximately USD 5.4 billion to strengthen Medicare, while federal hospital funding exceeds USD 22.5 billion annually. Complementing this, major projects such as the USD 600 million Rouse Hill Hospital and the USD 1.3 billion Bankstown Hospital redevelopment highlight ongoing capacity expansion . These initiatives are significantly increasing healthcare access and diagnostic infrastructure nationwide.

This expansion is directly translating into higher diagnostic volumes, creating strong demand for laboratory automation systems. Newly developed facilities, including the USD 1 billion Footscray Hospital and the USD 60 million Temora Hospital redevelopment, incorporate modern clinical and diagnostic services. As patient inflow increases, hospitals and laboratories must process larger sample volumes with greater efficiency and accuracy. This creates a clear cause-and-effect relationship, where infrastructure growth drives the need for scalable and automated laboratory workflows.

The opportunity is particularly advantageous for new entrants and emerging players due to evolving procurement needs and technology requirements. Expanding healthcare facilities require flexible, modular, and interoperable automation systems that can be integrated into newly built infrastructure. Unlike legacy systems, these environments allow the adoption of innovative solutions from smaller and specialized vendors. This shift reduces entry barriers and enables new players to compete by offering cost-effective, scalable, and technologically advanced automation solutions tailored to modern laboratory needs.

Australia Lab Automation Market Challenge:

High Initial Investment Costs

High initial investment costs represent a critical structural barrier in Australia’s laboratory automation market, driven by capital-intensive technologies and constrained capital allocation. Advanced automation systems require significant upfront spending on equipment, integration, and digital infrastructure. According to the Australian Institute of Health and Welfare, Australia’s total health expenditure reached approximately USD 178 billion in 2023–24, reflecting rising system-wide cost pressures. These increasing expenditures limit the availability of discretionary capital for advanced automation investments.

The challenge is further intensified by the elevated costs of medical technologies and competing investment priorities within the healthcare system. Reports indicate that certain medical devices in Australia can cost up to USD 25,000 more than international benchmarks due to regulatory pricing frameworks. Additionally, major investments in hospital construction and workforce expansion continue to dominate funding allocation decisions. As a result, healthcare providers often prioritize immediate service delivery needs over long-term automation upgrades.

This cost burden materially restricts market expansion by slowing procurement cycles and limiting adoption among mid-sized and regional laboratories. While automation technologies can deliver efficiency gains and potential system savings exceeding USD 3 billion annually, the high upfront investment creates a significant financial barrier. Consequently, laboratories delay modernization initiatives, reducing scalability and limiting broader adoption of laboratory automation solutions across Australia’s healthcare ecosystem.

Australia Lab Automation Market (2026-32) Segmentation Analysis:

The Australia Lab Automation Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2026–32 at the country level. Based on the analysis, the market has been further classified as;

Based on Product Type:

• Equipment / Devices
• Software
• Services

The Equipment / Devices dominate the Australia Laboratory Automation Market, accounting for approximately 55% of total demand, primarily because laboratory operations are inherently dependent on physical automation systems to process and manage high testing volumes. According to the Australian Institute of Health and Welfare, millions of diagnostic tests are conducted annually under Australia’s publicly funded healthcare system, supported by Medicare. These large-scale testing requirements necessitate automated liquid handling systems, robotic workstations, and sample processing instruments that directly handle laboratory workflows, making equipment the core spending component.

This dominance is further reinforced by the ongoing expansion of healthcare infrastructure and diagnostic capacity across Australia. Government-backed investments, including multi-billion-dollar hospital developments and upgrades to clinical facilities, are increasing the number of laboratories and testing centers. Each new or upgraded facility requires the installation of core automation equipment such as analyzers, storage systems, and sample handling technologies. Unlike software, which is layered onto existing systems, equipment represents a foundational requirement for laboratory setup, driving higher capital expenditure and market share.

Additionally, equipment benefits from long lifecycle usage, standardization, and a critical role in ensuring accuracy and throughput in diagnostic processes. Leading providers such as Thermo Fisher Scientific and F. Hoffmann-La Roche Ltd continue to invest in advanced automation platforms that improve precision and scalability. These systems are essential for maintaining quality standards and regulatory compliance in diagnostic testing. As a result, the combination of high upfront investment, essential functionality, and infrastructure-driven demand continues to position equipment as the dominant segment in Australia’s laboratory automation market.

By End User

• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes

The Pharmaceutical & Biotechnology Companies segment dominates the Australia Laboratory Automation Market, accounting for around 42% of total demand, primarily because drug discovery and development activities rely heavily on high-throughput, precision-driven laboratory workflows. These organizations require automated systems for screening, sample preparation, and data analysis to accelerate research timelines and improve reproducibility. According to the Australian Trade and Investment Commission, Australia’s life sciences sector continues to expand, supported by strong clinical trial activity and a globally recognized research ecosystem. This sustained R&D intensity directly drives demand for advanced laboratory automation technologies.

Industrial and research infrastructure further reinforces this dominance by enabling large-scale experimentation and continuous innovation. Australia hosts a growing number of biotechnology firms and research partnerships supported by government initiatives such as the Medical Research Future Fund, which allocates billions of dollars toward health and medical research. These investments support genomics, precision medicine, and biologics development, all of which require automated laboratory environments for efficient data handling and experimental throughput. Unlike diagnostic laboratories, which focus on routine testing, pharmaceutical and biotechnology companies operate complex workflows that inherently demand higher automation intensity.

Additionally, the need for regulatory compliance, reproducibility, and faster time-to-market strengthens automation adoption within this segment. Companies must adhere to stringent international standards for drug development, requiring accurate and traceable laboratory processes. Automation systems help minimize human error, ensure consistency, and support scalable research operations. Leading players such as Thermo Fisher Scientific and Danaher Corporation provide integrated automation platforms tailored for pharmaceutical applications. This combination of R&D intensity, funding support, and regulatory requirements continues to position pharmaceutical and biotechnology companies as the dominant end-user segment in Australia.

Gain a Competitive Edge with Our Australia Lab Automation Market Report:

• Australia Lab Automation Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• Australia Lab Automation Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.